Witjes - Figure 52
TCTh, a 1-center experience
FIG. 52: We have analyzed our experience with chemohyperthermia since we started using it in 2002.[43] We looked at 160 patients and found that 129, >80%, were BCG failures. That is atypical of the patients who are referred to us for this treatment. Recurrence-free survival after 1 and 2 years was almost 60% and 50%, respectively, and only 4% of patients experienced progression. So if chemohyperthermia is available, it is certainly an option to keep in mind.
References
[43]
Arends TJ, van der Heijden AG, Witjes JA, et al. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol. 2014;192:708−13 http://dx.doi.org/10.1016/j.juro.2014.03.101
